This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacogenomic Research in Korean Patients With Hepatitis C

This study has been completed.
Information provided by (Responsible Party):
Jae-Gook Shin, Inje University Identifier:
First received: October 13, 2011
Last updated: May 30, 2013
Last verified: May 2013
The aim of this study is to investigate the relationships between drug response and the host genetic factors, viral factors and clinical factors in chronic hepatitis C patients (HCV). And thus, the investigators are trying to develop the pharmacogenomic guideline in the Korean patients with HCV.

Chronic Hepatitis C

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Pharmacogenomic Research for Prediction of Drug Response in Korean Patients With Hepatitis C

Resource links provided by NLM:

Further study details as provided by Jae-Gook Shin, Inje University:

Primary Outcome Measures:
  • Sustained virological response (SVR) [ Time Frame: 24 weeks after the end of treatment ]
    Undetectable HCV RNA in serum ( <15 IU/ml ) 24 weeks after the end of treatment

Secondary Outcome Measures:
  • Anemia [ Time Frame: 4 weeks after start of treatment ]
    1. a reduction in Hemoglobin of >3.0 g/dL
    2. a reduction in Hemoglobin levels to 10.0g/dL.

Biospecimen Retention:   Samples With DNA
DNA extracted from blood

Enrollment: 373
Study Start Date: July 2011
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
SVR group
A patients who achieved SVR (sustained virologic response)
non-SVR group
A patients who not achieved SVR (sustained virologic response)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Korean patients with chronic hepatitis C

Inclusion Criteria:

  • Hepatitis C virus infected patients

Exclusion Criteria:

  • Patients who infected Hepatitis B virus or Human immunodeficiency virus
  • HCV infected patients previously treated with antiviral drugs
  • Patients had a history of autoimmune hemolytic anemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01453244

Korea, Republic of
Inje University
Busan, Korea, Republic of, 633-165
Sponsors and Collaborators
Inje University
Principal Investigator: Jae-Gook Shin, M.D, phD Inje University
  More Information

Responsible Party: Jae-Gook Shin, Inje University Identifier: NCT01453244     History of Changes
Other Study ID Numbers: 11-037
Study First Received: October 13, 2011
Last Updated: May 30, 2013

Keywords provided by Jae-Gook Shin, Inje University:
Chronic hepatitis C

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections processed this record on September 19, 2017